Precision Brain Health Research Act of 2026
Summary
HR8115, the Precision Brain Health Research Act of 2026, expands the VA's Scott Hannon Initiative to include biomarkers for repetitive low-level blast exposure and dementia, and mandates a VA-DoD data-sharing partnership. The bill is in early legislative stages (referred to committees) with no authorized funding, limiting near-term market impact. Healthcare IT and diagnostic companies may see modest contract opportunities, but material revenue effects are unlikely without appropriations.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8115 is an early-stage authorization bill with no appropriated funding, limiting near-term market impact.
- 2.The bill expands VA brain health research to include blast exposure and dementia, but does not specify dollar amounts.
- 3.Healthcare IT and diagnostic companies may see minor contract opportunities, but revenue impact is negligible relative to their size.
Market Implications
The bill's impact on healthcare and defense sectors is minimal at this stage. No real market data is provided, but structural analysis shows that VA research contracts are a small fraction of revenue for large-cap companies like UNH ($371.6B revenue) and LH ($12.8B). Investors should monitor appropriations bills for actual funding before expecting any market reaction.
Full Analysis
HR8115 was introduced on March 26, 2026, by Rep. Miller-Meeks (R-IA) and referred to the Veterans' Affairs and Armed Services committees. The bill amends the existing Scott Hannon Initiative to add repetitive low-level blast exposure and dementia to the list of conditions for biomarker research, and requires a VA-DoD data-sharing partnership. As an authorization bill, it sets policy but does not appropriate funds; actual spending requires a separate appropriations bill. The bill has one cosponsor (Rep. Kiggans, R-VA) and no further legislative action since referral, indicating low momentum. The money trail is unclear: no dollar amounts are specified, and the VA's existing research budget would likely absorb any costs. Companies like UNH (Optum), LH, DGX, GEHC, and LDOS could see minor contract opportunities for data analytics, diagnostics, imaging, and IT integration, but these are speculative and small relative to their revenues. The bill's early stage and lack of funding make material market impact unlikely in the near term.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Requires VA to conduct research studies on repetitive low-level blast exposure and validate brain health biomarkers, increasing demand for diagnostic testing and biomarker analysis.
Who must act
Department of Veterans Affairs, which must conduct research studies and validate biomarkers for brain conditions.
What happens
Increased procurement of biomarker testing services and laboratory analysis for VA research on blast exposure, dementia, and other brain conditions.
Stock impact
LH provides diagnostic testing services; VA contracts for biomarker validation could generate modest revenue, but LH's $12.8B annual revenue makes this a small fraction.
What the bill does
Same as LH: VA research studies on blast exposure biomarkers increase demand for diagnostic testing.
Who must act
Department of Veterans Affairs.
What happens
Increased procurement of biomarker testing services for VA research.
Stock impact
DGX provides diagnostic testing; potential VA contracts for biomarker validation, but revenue impact is minimal relative to DGX's $9.3B annual revenue.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
EVEST Act
Saving Lives and Reducing Health Care Waste by Improving Diagnosis in Medicine Act
To amend title XXVII of the Public Health Service Act and title XIX of the Social Security Act to require coverage of Alzheimer's biomarker testing under group health plans, group and individual health insurance coverage, and the Medicaid program.
Department of Homeland Security Appropriations Act, 2027
Slash the Pentagon Act
LEIDOS BIOMEDICAL RESEARCH INC: $338M Department of Health and Human Services Contract
To amend the Homeland Security Act of 2002 to direct the Secretary of Homeland Security, acting through the Commissioner of U.S. Customs and Border Protection, to implement large-scale, non-intrusive inspection technology at land ports of entry identified as high risk, and for other purposes.
To prohibit Federal agencies from purchasing or accessing automated surveillance systems that identify, track, or record individuals, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Further Strengthening Actions Taken to Adjust Imports of Aluminum into the United States
This proclamation modifies the Section 232 tariff regime on aluminum imports by authorizing the Secretary of Commerce to establish a program that incentivizes new U.S. investment in primary aluminum production. Companies with approved onshoring plans can import primary aluminum at half the standard Section 232 duty rate, up to the anticipated annual output of their new or expanded facilities, with construction required to start by January 20, 2029. The action aims to boost domestic primary aluminum supply for national security and defense industrial base needs.
Securing America’s Defense Supply Chains and Ensuring Domestic Acquisition of Critical Materials
This executive order restricts waivers for foreign-sourced critical materials in defense contracts, effective January 1, 2027, and mandates that defense contractors map their supply chains from raw materials to end products, vet subcontractors for risks, and prohibit covered materials from unreliable foreign suppliers. It directs the Secretary of War to enforce strict compliance, including requiring mitigation plans for any non-compliant materials and establishing penalties for fraud or willful noncompliance.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →